Infographic
Alzheimers Disease Infographic
Alzheimer's Disease is the most common type of dementia accounting for 60%-80% of all cases. In the past 5 years, PRA has conducted numerous clinical…
All Results
Infographic
White Paper
PRA Insights Report: Alzheimer's Disease Research
This PRA Insights report focusing on Alzheimer’s disease research was compiled from survey data gathered at the 2017 Alzheimer’s Association…
White Paper
Alzheimer's Disease Research 2018
PRA conducted a survey at the 2018 Alzheimer's Association International Conference in Chicago. Across the board we found that the research community…
Capability
Pain Studies at PRA Early Development Services
PRA Health Sciences offers a range of pain models to assess pain perception and the efficacy of experimental analgesics in healthy volunteers and…
Case Study
Program Challenges Strengthen Partnership
PRA Health Sciences was selected to conduct a global program of studies that targeted 2,200+ patients with multiple sclerosis (MS). Although there…
Fact Sheet
CSF Sampling
PRA understands how cerebrospinal fluid (CSF) sampling benefits our clients’ early phase trials. We regularly conduct CSF sampling to collect key PK…
Case Study
PRA Teamwork Demonstrates Vision
A large pharmaceutical client selected PRA to conduct 2 Phase III epilepsy studies in India, Eastern and Western Europe, and Australia. PRA’s project…
Fact Sheet
Data Monitoring Committee Unit
Due to increasing regulatory requirements, the need for quality study and patient safety data is critical as we work together to bring our clients’…
Poster
Marijuana Effect on Differentiating an Opioid from Placebo During the Discrimination Phase of a Human Abuse Potential Study
Subjects of human abuse potential (HAP) studies must be able to detect liking with the investigational drug. However, many subjects recruited for HAP…
Poster
A Retrospective Analysis of the Effects of Protocol Design on Completion Rates in Outpatient Clinical Trials in Subjects with Schizophrenia or Schizoaffective Disorder
Subject attrition from randomized Schizophrenia trials is a significant problem and has been found in a meta-analysis to be as high as 76%. The…